ARA and DHA in BPD Outcomes: A Greek RCT

The NICU at Papageorgiou Hospital in Thessaloniki is now starting a new study with NeoMega36. They will look into the Bronchopulmonary Dysplasia (BPD) and morbidity outcomes after implementing NeoMega36 at their unit.

BPD is a common complication affecting over 50 % of infants born before 28 weeks’ gestational age. BPD is mainly caused by prevented pulmonary development and sustained postnatal inflammation aggravated by oxidative stress and mechanical ventilation. It affects over 85 % of infants born before week 29.

Dr Maria Lithoxopoulou, Assistant Professor in Neonatology and Paediatrics, is one of the clinicians involved in the project. We got the chance to ask Dr Lithoxopoulou some quick questions regarding ARA and DHA supplementation.

How did you first hear about NeoMega36?

I was introduced to NeoMega36 by representatives at Neobiomics during a medical congress.

What made you interested in ARA and DHA research?

I believe ARA and DHA supplementation may offer significant benefits in managing bronchopulmonary dysplasia (BPD), similar to the positive outcomes previously observed in retinopathy of prematurity (ROP).

How do you see the future of ARA and DHA in neonatal care?

I believe ARA and DHA supplementation may offer significant benefits in managing bronchopulmonary dysplasia (BPD), similar to the positive outcomes previously observed in retinopathy of prematurity (ROP).